MACUGEN RECEIVES POSITIVE OPINION FROM EUROPE'S CHMP FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION

Pfizer Inc said today that the Committee for Human Medicinal Products (CHMP) has adopted a positive opinion recommending marketing authorization of Macugen (pegaptanib sodium injection) in the European Union for the treatment of neovascular (wet) age-related macular degeneration (AMD). Pfizer anticipates the European Commission to grant a marketing authorization by the end of the year.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-16-2005/0004108959&EDATE=)